Alzheon Appoints Chair
This article was originally published in Scrip
Executive Summary
Alzheon, Inc. has appointed former GlaxoSmithKline CEO Jean-Pierre Garnier chair of its board of directors. From 2000 to 2008, Garnier was the first CEO of GSK after SmithKline Beecham and Glaxo Wellcome merged and before that he was CEO of SmithKline Beecham. Prior to this he was president of Schering-Plough and after his retirement from GSK, he was CEO of Pierre Fabre Laboratories and chair of Cerenis (US).
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.